Castle Biosciences files updated pro forma financials for Cernostics acquisition

CASTLE BIOSCIENCES INC

Pro forma net loss of $38.9M for FY2021, including $3.6M in transaction accounting adjustments.
Pro forma revenue of $94.7M, reflecting Cernostics' $0.6M contribution.
Pro forma diluted loss per share of $1.55, compared to Castle standalone $1.24.
Pro forma operating loss of $47.7M, up from $40.1M standalone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.